Department of Cardiology, Aarhus University hospital, Skejby
Aarhus N, 8200, Denmark
NCT Number: NCT00482651
Atherosclerosis is a chronic and multifocal immunoinflammatory, fibroproliferative disease of medium-sized and large arteries driven by lipid. Atherosclerosis is rarely fatal unless thrombosis supervene, causing an acute coronary syndrome. Therefore, for event-free survival, the vital question is not why atherosclerosis develops but rather why atherosclerosis, after years after indolent growth, suddenly becomes complicated with luminal thrombosis.
The great majority of coronary plaques will remain quiescent, at least from a clinical point of view.
Acute coronary syndrome is primarily precipitated by a ruptured plaque. The precipitating factor or condition may be found outside rather than inside the plaque.
The challenge is to find the plaque(s) destined for the next thrombus-mediated heart attack(s), treat, and thus avoid the heart attack(s). Identification of vulnerable plaques has become a key issue. The natural history of individual plaques (risk of thrombosis) is unknown and needs to be established.
Multidetector computed tomography (MDCT) can provide angiography and imaging of the vessel wall (detection, quantification and characterization of plaques).
The intention of this project is to evaluate the accuracy of coronary MDCT in identifying and differentiating the morphology of coronary atherosclerotic plaques.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aarhus N, 8200, Denmark
Atherosclerosis without thrombosis is rarely fatal. It is the acute thrombotic complications which account for disability and death. Therefore, for event-free survival, the question is not why atherosclerosis develops but rather why atherosclerosis, after years after indolent growth, suddenly becomes complicated with luminal thrombosis.
Post-mortem and clinical observations indicate that patients with acute coronary syndromes often have many ruptured and/or active plaques in their coronary arteries.
The challenge is to find the plaque(s) destined for the next thrombus-mediated heart attack(s), treat, and thus avoid the heart attack(s). Identification of vulnerable plaques have become a key issue. The natural history of individual plaques (risk of thrombosis) is unknown and needs to be established. Multidetector computed tomography (MDCT) can provide angiography and imaging of the vessel wall.
Hypothesis:
It is by CT-scanning possible to 1a) identify and differentiate the morphology of coronary atherosclerotic plaques.
1b) identify vulnerable plaques.
Materials and methods:
Research plan:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
contrast Multidetector CT-scanning
Other names: Philips Brilliance 64
CAG and if necessary PCI. Included patients are already assigned for CAG
During CAG Intravascular Ultrasound will be performed in the three coronary arteries
Other names: Volcano / virtual histology
a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
Time frame: immediately after the CT-scanning
Time frame: immediately after the CT-scanning
Time frame: one year
University of Aarhus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05906797
Arterial Occlusive Diseases, Arteriosclerosis
Catania, Italy
View Trial DetailsNCT02991703
Arterial Occlusive Diseases, Arteriosclerosis
Nantes, France
View Trial DetailsNCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT02505399
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Haute-Garonne, France
View Trial Details